

## CLINICAL REVIEW

### Clinical Review Section

**MO comments:**

*In the daptomycin arm, cure rates were higher in patients with abscesses while cure rates were lower in patients with infected ulcer (non-diabetic) compared to the comparator arm. In patients with abscesses, incision and drainage itself can be curative. Patients with non-diabetic ulcers included patients with venous ulcers, and decubitus ulcers, both of which are associated with decreased tissue perfusion. This may account for the lower cure rates seen in the daptomycin arm. Patients with history of diabetes had slightly lower cure rates compared to those without history of diabetes in the comparator arm; no difference was seen in the daptomycin arm.*

**F. Oral switch**

Clinical success rates by treatment group were also compared for those patients who did and did not have oral switch therapy. Among patients in the MITT population who received only intravenous therapy, the clinical success rates were 67.0% (128/191) and 66.5% (125/188) for daptomycin and the comparator groups, respectively. Among the 46 patients in the MITT population who were switched to oral therapy, the clinical success rates were 66.7% (12/18) in the daptomycin group and 70.0% (17/24) in the comparator group.

**Table 39: SDCO by oral switch status (Population: MITT)**

| Oral switch | Clinical Response    | Daptomycin  | Comparator  | 95% CI     |
|-------------|----------------------|-------------|-------------|------------|
| No          | No of patients       | 191         | 188         | -10.0, 9.0 |
|             | Clinical Success     | 128 (67.0%) | 125 (66.5%) |            |
|             | Cure                 | 80 (41.9%)  | 71 (37.8%)  |            |
|             | Clinical Improvement | 48 (25.1%)  | 54 (28.7%)  |            |
|             | Clinical Failure     | 63 (33.0%)  | 63 (33.5%)  |            |
|             | Failure              | 43 (22.5%)  | 41 (21.8%)  |            |
|             | Unable to Evaluate   | 20 (10.5%)  | 22 (11.7%)  |            |
| Yes         | No of patients       | 18          | 24          |            |
|             | Clinical Success     | 12 (66.7%)  | 17 (70.8%)  |            |
|             | Cure                 | 11 (61.1%)  | 14 (58.3%)  |            |
|             | Clinical Improvement | 1 (5.6%)    | 3 (12.5%)   |            |
|             | Clinical Failure     | 6 (33.3%)   | 7 (29.2%)   |            |
|             | Failure              | 4 (22.2%)   | 6 (25.0%)   |            |
|             | Unable to Evaluate   | 2 (11.1%)   | 1 (4.2%)    |            |

Source: Table 14.2.1.23

## CLINICAL REVIEW

### Clinical Review Section

#### MO Comments:

*Only a small number of patients were switched to oral therapy consistent with this primarily being an in-patient study. Review of a random sample of case report forms had identified that several investigators made errors in the timing of study visits relative to switch to oral antibiotics. However, for efficacy analyses the sponsor only utilized the appropriate visit window for TOC visit after oral medications were stopped. The overall efficacy analyses were thus not affected.*

#### F. Concomitant procedures

Patients with surgical procedures (debridement, curettage, incision and drainage etc) were flagged. Results of an analysis separating patients into those who did and did not have these procedures are provided in table 40.

**Table 40: SDCO by concomitant surgical procedures  
(Population: ITT)**

| Concomitant Procedures | Daptomycin (N=264) | Comparator (N=266) | 95% C.I.       |
|------------------------|--------------------|--------------------|----------------|
| Yes                    | 49/75 (65.3%)      | 57/78 (73.1%)      | (-23.6%, 8.2%) |
| No                     | 116/189 (61.4%)    | 105/188 (55.9%)    | (-4.9%, 16.0%) |

### RESULTS (Study 9901)

#### Disposition of Patients

A total of 571 patients were randomized, 277 to receive daptomycin and 294 to receive comparator. Nine randomized patients discontinued prior to receiving any study treatment. Of the 562 patients who received at least one dose of study drug, 270 were randomized to the daptomycin arm and 292 to the comparator arm. One subject (0410100063) who was randomized to receive daptomycin but received comparator was considered misrandomized. In all efficacy analyses data for this subject are tabulated as randomized i.e., in the daptomycin arm and in all safety analyses as treated i.e. in the comparator arm.

Of the 293 patients treated with comparator drugs, 227 (77.5%) received semisynthetic penicillins (149 received cloxacillin, 59 received oxacillin, 19 received flucloxacillin), 64 (21.8%) received vancomycin and two received vancomycin in combination with flucloxacillin.

#### Comments:

*Unlike in study 9801, semisynthetic penicillins were more commonly used as comparator agents rather than vancomycin, reflecting local antibiotic use patterns and prevalence of antibiotic resistant strains. For susceptible*

## CLINICAL REVIEW

### Clinical Review Section

*organisms including methicillin-susceptible S. aureus, bactericidal activity of semisynthetic penicillins is superior to that of vancomycin. This may have contributed to the lower cure rates in the comparator arm in study 9801 compared to 9901.*

Over 90% of patients in both treatment groups completed i.v. treatment as planned. The number of premature discontinuations were 18 (6.7%) and 13 (4.4%) in the daptomycin and comparator arms respectively. The most common reason for premature discontinuation in both treatment arms was adverse event (2.6% and 1.7% in the daptomycin and comparator arms, respectively). No patients discontinued study medication due to elevation in CPK. Table 39 presents a summary of subject disposition during the study.

**Table 41 (Sponsor Table 10-1): Subject Disposition**

| Population                       | Daptomycin             | Comparator   |
|----------------------------------|------------------------|--------------|
| Randomized                       | 277                    | 294          |
| Randomized But Not Treated       | 7                      | 2            |
| Intent-to-Treat Population       | 270                    | 292          |
| Misrandomized                    | 1                      | 0            |
| Safety Population                | 269 (100.0%)           | 293 (100.0%) |
| Completed Therapy                | 251 (93.3%)            | 280 (95.6%)  |
| Prematurely Discontinued Therapy | 18 (6.7%) <sup>2</sup> | 13 (4.4%)    |
| Adverse Event                    | 7 (2.6%)               | 5 (1.7%)     |
| Clinical Failure                 | 4 (1.5%)               | 3 (1.0%)     |
| Subject's Decision               | 3 (1.1%)               | 4 (1.4%)     |
| Protocol Violation               | 2 (0.7%)               | 0 (0.0%)     |
| Lost to Follow-up                | 0 (0.0%)               | 1 (0.3%)     |
| Death                            | 2 (0.7%)               | 0 (0.0%)     |

#### **Protocol Deviations**

#### **Eligibility Deviations**

One or more eligibility deviations were reported for 32 (11.9%) patients in the daptomycin arm and 47 (16.1%) in the comparator arm. The most commonly reported deviation was serum CPK >50% above upper limit of normal (ULN) at baseline and was reported in 7.0% and 7.5% of patients in the daptomycin and comparator arms respectively. Elevations in CPK were generally considered to reflect prior trauma to the tissue at the primary site of infection, surgical incision and debridement, and intramuscular injections. All other deviations were reported in ≤2% of patients in either treatment group. Table 42 tabulates deviations that were reported in two or more patients.

Clinical Review Section

**Table 42 (Sponsor Table 10-2): Eligibility deviations reported in ≥ 2 patients (Intent-to-Treat)**

| <b>Deviation</b>  | <b>Daptomycin<br/>N = 270</b> | <b>Comparator<br/>N = 292</b> |
|---|-------------------------------|-------------------------------|
| CPK >50% above ULN  | 19 (7.0%)                     | 22 (7.5%)                     |
| X-rays not obtained at baseline for infections proximal to bone                         | 3 (1.1%)                      | 6 (2.1%)                      |
| Specimen available for Gram stain, culture and susceptibility test within 48 hr         | 3 (1.1%)                      | 5 (1.7%)                      |
| Did not have diagnosis of Gram positive skin infection with complicating factor         | 4 (1.5%)                      | 3 (1.0%)                      |
| Two sets of blood cultures not obtained within 48 hours prior to first dose             | 3 (1.1%)                      | 2 (0.7%)                      |
| Calculated creatinine clearance < 30 mL/min or serum creatinine >1.9 mg/dL (170 μmol/L) | 1 (0.4%)                      | 4 (1.4%)                      |
| Age <18 or > 85 years (18 to 65 for South African sites)                                | 1 (0.4%)                      | 2 (0.7%)                      |
| Multiple infected ulcers at distant sites   | 2 (0.7%)                      | 0 (0.0%)                      |

Two patients were discontinued from the study due to protocol violations. Subject 0310100054 was discontinued after receiving 4 doses of daptomycin when the baseline wound culture was reported as yielding only Gram-negative rods. Subject 0401100061 was discontinued after receiving one dose of daptomycin when it was noted that the subject was also receiving flucloxacillin in error.

**MO Comments:**

*Most protocol violations were of a minor nature and were similar in the two arms. They are unlikely to impact assessment of drug efficacy. Enrollment of patients with elevated CPK could impact safety assessments.*

**Data Sets Analyzed**

The ITT population includes all patients who received at least one dose of study treatment. The MITT population represents all ITT patients who had an infecting Gram positive pathogen isolated at baseline. In the comparator arm, 87.3% of patients were included in the MITT population compared to 78.9% in the daptomycin arm.

The CE population includes approximately 90% of patients in both treatment arms. Fourteen (5.2%) patients in the daptomycin arm and 20 (6.8%) in the comparator arm were excluded from the CE population by the sponsor as no evaluation was conducted during the TOC window. Twelve (4.4%) patients in the daptomycin arm and 10 (3.4%) in the comparator arm were excluded from the CE population because they received potentially effective non-study antibiotics either prior to treatment or post-baseline for reasons other than therapeutic failure. Seven

## CLINICAL REVIEW

### Clinical Review Section

patients in the daptomycin arm and eight patients in the comparator arm were excluded from the CE population as they received an inadequate duration of treatment or < 80% of expected dose.

The ME population comprises all patients in the CE population who had an infecting Gram positive pathogen isolated at baseline, ~73% and ~79% of ITT patients in the daptomycin and comparator arms respectively were included in the ME population. Table 43 presents the patient populations used for efficacy analysis.

**Table 43 (Sponsor Table 11-1): Patient populations for efficacy analyses**

| Population                               | Daptomycin   | Comparator   |
|--|--------------|--------------|
| Intent-to-Treat                          | 270 (100.0%) | 292 (100.0%) |
| Modified Intent-to-Treat                 | 213 (78.9%)  | 255 (87.3%)  |
| No Baseline Pathogen                     | 57 (21.1%)   | 37 (12.7%)   |
| Clinically Evaluable                     | 245 (90.7%)  | 262 (89.7%)  |
| Not Clinically Evaluable                 | 25 (9.3%)    | 30 (10.3%)   |
| No Evaluation in the Test-of-Cure Window | 14 (5.2%)    | 20 (6.8%)    |
| Dosing Compliance                        | 7 (2.6%)     | 8 (2.7%)     |
| Post-baseline Effective Antibiotic       | 5 (1.9%)     | 4 (1.4%)     |
| Prior Effective Antibiotic               | 4 (1.5%)     | 3 (1.0%)     |
| Sponsor Override                         | 3 (1.1%)     | 3 (1.0%)     |
| Misrandomized                            | 1 (0.4%)     | 0 (0.0%)     |
| Microbiologically Evaluable              | 196 (72.6%)  | 231 (79.1%)  |
| Not Microbiologically Evaluable          | 74 (27.4%)   | 61 (20.9%)   |

### Demographic and Other Baseline Characteristics

#### Demographic Characteristics

The two treatment groups were well balanced with regard to all demographic characteristics. Majority of patients was male and Caucasian. Mean age of patients was 47.9 years in the daptomycin group and 48.6 years in the comparator group. Approximately 20% of patients in both treatment groups were ≥65 years of age at study entry. Table 44 presents a summary of the demographic characteristics.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.